Filament Health Corp. (NEO:FH)

Market Cap	35.82K -99.7%
Revenue (ttm)	458.54K -78.7%
Net Income	-4.11M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	929,483
Open	0.0100
Previous Close	0.0150
Day's Range	0.0050 - 0.0150
52-Week Range	0.0050 - 0.0700
Beta	0.91
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 14, 2026

About Filament Health

Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. The company’s leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. It also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, the company provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is h...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Benjamin Lightburn
• Country: Canada
• Stock Exchange: Cboe Canada
• Ticker Symbol: FH

Financial Performance

In 2024, Filament Health's revenue was 616,678, a decrease of -71.06% compared to the previous year's 2.13 million. Losses were -4.97 million, -6.61% less than in 2023.